An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes
- PMID: 21525169
- DOI: 10.1124/dmd.111.038596
An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes
Abstract
Metabolism-dependent inhibition (MDI) of cytochrome P450 is usually assessed in vitro by examining whether the inhibitory potency of a drug candidate increases after a 30-min incubation with human liver microsomes (HLMs). To augment the IC(50) shift, many researchers incorporate a dilution step whereby the samples, after being preincubated for 30 min with a high concentration of HLMs (with and without NADPH), are diluted before measuring P450 activity. In the present study, we show that the greater IC(50) shift associated with the dilution method is a consequence of data processing. With the dilution method, IC(50) values for direct-acting inhibitors vary with the dilution factor unless they are based on the final (postdilution) inhibitor concentration, whereas the IC(50) values for MDIs vary with the dilution factor unless they are based on the initial (predilution) concentration. When the latter data are processed on the final inhibitor concentration, as is commonly done, the IC(50) values for MDI (shifted IC(50) values) decrease by the magnitude of the dilution factor. The lower shifted IC(50) values are a consequence of data processing, not enhanced P450 inactivation. In fact, for many MDIs, increasing the concentration of HLMs actually leads to considerably less P450 inactivation because of inhibitor depletion and/or binding of the inhibitor to microsomes. A true increase in P450 inactivation and IC(50) shift can be achieved by assessing MDI by a nondilution method and by decreasing the concentration of HLMs. These results have consequences for the conduct of MDI studies and the development of cut-off criteria.
Similar articles
-
Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.J Appl Toxicol. 2013 Feb;33(2):100-8. doi: 10.1002/jat.1720. Epub 2011 Sep 14. J Appl Toxicol. 2013. PMID: 21915887
-
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.Drug Metab Dispos. 2011 Jun;39(6):1054-7. doi: 10.1124/dmd.111.038208. Epub 2011 Mar 10. Drug Metab Dispos. 2011. PMID: 21393461
-
Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design.Xenobiotica. 2009 Feb;39(2):99-112. doi: 10.1080/00498250802638155. Xenobiotica. 2009. PMID: 19255936
-
Exploring concepts of in vitro time-dependent CYP inhibition assays.Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):157-74. doi: 10.1517/17425255.2014.856882. Epub 2013 Nov 21. Expert Opin Drug Metab Toxicol. 2014. PMID: 24256452 Review.
-
Recent examples of novel secondary metabolites.Folia Microbiol (Praha). 1995;40(1):31-42. doi: 10.1007/BF02816526. Folia Microbiol (Praha). 1995. PMID: 8851465 Review.
Cited by
-
Consideration of Nevirapine Analogs To Reduce Metabolically Linked Hepatotoxicity: A Cautionary Tale of the Deuteration Approach.Chem Res Toxicol. 2023 Sep 28;36(10):1631-42. doi: 10.1021/acs.chemrestox.3c00192. Online ahead of print. Chem Res Toxicol. 2023. PMID: 37769118
-
The impact of CYP2C19 genotype on phenoconversion by concomitant medication.Front Pharmacol. 2023 Jun 8;14:1201906. doi: 10.3389/fphar.2023.1201906. eCollection 2023. Front Pharmacol. 2023. PMID: 37361233 Free PMC article.
-
Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.Clin Transl Sci. 2023 Jun;16(6):987-1001. doi: 10.1111/cts.13504. Epub 2023 Apr 28. Clin Transl Sci. 2023. PMID: 36967488 Free PMC article.
-
In vitro metabolic characterization of the SARS-CoV-2 papain-like protease inhibitors GRL0617 and HY-17542.Front Pharmacol. 2023 Feb 15;14:1067408. doi: 10.3389/fphar.2023.1067408. eCollection 2023. Front Pharmacol. 2023. PMID: 36874001 Free PMC article.
-
Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism.Pharmaceutics. 2022 Feb 22;14(3):477. doi: 10.3390/pharmaceutics14030477. Pharmaceutics. 2022. PMID: 35335853 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical